Remodulin® Archives - UTHR PIPELINE

RemoLife (treprostinil): Product

RemoLife
(treprostinil)

Therapeutic Platform
Remodulin®

Targeted Indication
Pulmonary Hypertension (PH) WHO Group 1 (PAH)

Status
Devices / Prototype development

Next-generation ambulatory micro-infusion pumps with smartphone compatibility.
LEARN MORE Close
RemoPro™ (treprostinil prodrug): Product

RemoPro™
(treprostinil prodrug)

Therapeutic Platform
Remodulin®

Targeted Indication
Pulmonary Hypertension (PH) WHO Group 1 (PAH)

Status
Phase 1

Prodrug of treprostinil that is being developed to reduce site pain associated with subcutaneous delivery of treprostinil.
LEARN MORE Close

Program Updates

June 16, 2021

United Therapeutics Announces FDA Acceptance of Tyvaso DPI™ New Drug Application For Priority Review

June 3, 2021

United Therapeutics Announces First Patient Enrolled in Phase 3 TETON Study of Tyvaso in Patients With Idiopathic Pulmonary Fibrosis

April 1, 2021

United Therapeutics Announces FDA Approval And Launch Of Tyvaso® For The Treatment Of Pulmonary Hypertension Associated With Interstitial Lung Disease

RemoLife
(treprostinil)

RemoPro™
(treprostinil prodrug)

Program Updates

Idiopathic Pulmonary Fibrosis (IPF)

Neuroblastoma

INCREASE
(inhaled treprostinil)

Tyvaso DPI™
(inhaled treprostinil)

Centralized Ex-Vivo Lung Evaluation System
(EVLP)

RemoLife
(treprostinil)

PERFECT
(inhaled treprostinil)

OreniPro™
(once-daily, oral treprostinil prodrug)

RemoPro™
(treprostinil prodrug)

TETON
(inhaled treprostinil)

ADVANCE Studies Ralinepag
(IP receptor agonist)

Unikidney
(xenokidney)

Uniheart
(xenoheart)

Unilobe
(Lung Lobes)

SAPPHIRE Aurora-GT™ eNOS Gene Therapy

Genetically-Enhanced Mesenchymal stem cells
(GEM)

U-Lung
(3DAP Lungs)

Pulmonary Arterial Hypertension (PAH) WHO Group 1

Pipeline / Therapeutic Platform / Remodulin®

Program Updates

Idiopathic Pulmonary Fibrosis (IPF)

Neuroblastoma

Pulmonary Arterial Hypertension (PAH) WHO Group 1